Nurix Therapeutics, Inc. (NRIX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 12.73 |
| Open | 13.15 |
| Bid | 12.75 x 600 |
| Ask | 12.86 x 100 |
| Day's Range | 12.70 - 13.73 |
| 52 Week Range | 4.22 - 18.12 |
| Volume | |
| Avg. Volume | 1,068,343 |
| Market Cap | 780.443M |
| Beta (5Y Monthly) | 2.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
- Zacks
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
- Zacks
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
© 2024 Yahoo. All rights reserved.